Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
In this issue
› Cerivastatin (Lipobay) withdrawn
› Reminder: Fluticasone propionate (Flixotide): use of high doses (>500 micrograms/twice daily) Propofol (Diprivan) infusion: sedation in children aged 16 years or younger contraindicated
› In Focus: Thiazolidinediones (glitazones) - rosiglitazone and pioglitazone
› Cardiodepressant effects of itraconazole (Sporanox)
› Reminder: New guidance for bupropion (Zyban)
› Psoralea corylifolia fruit in Traditional Chinese Medicines causing severe skin reactions
› Nevirapine (Viramune): Serious adverse reactions when used in HIV post exposure prophylaxis
› Reminder: Fructose and sorbitol containing parenteral solutions should not be used
› Reminder: Linezolid (Zyvox) and myelosuppression
› Oral iron supplements: accidental overdose may be fatal in children
› Electrosurgical equipment and risk of burns due to use of spirit-based solutions
› MMR vaccine and Idiopathic Thrombocytopenic Purpura
› Trastuzumab (Herceptin): prolonged half-life and possible anthracycline-associated cardiac toxicity
› More medicines available over-the-counter
› Next edition of Current Problems in Pharmacovigilance
Current Problems in Pharmacovigilance August 2001 
